Supplemental Figure 1 from Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Authors:
- Joseph M. TuscanoJTJoseph M. Tuscano
- Christina PohCPChristina Poh
- Paul KaesbergPKPaul Kaesberg
- Guilluame LuxardiGLGuilluame Luxardi
- Alexander MerleevAMAlexander Merleev
- Alina MarusinaAMAlina Marusina
- Ann BrunsonABAnn Brunson
- Aaron RosenbergARAaron Rosenberg
- Brian JonasBJBrian Jonas
- Emanual MaverakisEMEmanual Maverakis
Open Access
- 31 March 2023
- other
- Published by American Association for Cancer Research (AACR)